Home » USA Broker Ratings » Hologic, Inc. – Consenus Indicates Potential 1.9% Upside

Hologic, Inc. – Consenus Indicates Potential 1.9% Upside

Hologic, Inc. with ticker code (HOLX) now have 15 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The range between the high target price and low target price is between 53 and 42 with the average target price sitting at 48.53. With the stocks previous close at 47.62 this now indicates there is a potential upside of 1.9%. The 50 day moving average now sits at 47.06 and the 200 day MA is 45.6. The market cap for the company is $12,642m. Find out more information at: http://www.hologic.com

Hologic, Inc., a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health. The company offers Aptima molecular diagnostic assays, target capture/nucleic acid extraction technology, transcription-mediated amplification technology, hybridization protection and dual kinetic assay technologies, instrumentation, Invader chemistry platform, ThinPrep system, and rapid fetal fibronectin test products. It also provides breast imaging and analytics products, such as 2D and 3D mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, and breast biopsy and biopsy site markers, as well as localization, specimen radiology, ultrasound, and connectivity solutions. In addition, the company offers Selenia Dimensions and 3Dimensions gantries for performing 2D and tomosynthesis image acquisition and display; C-View and Intelligent 2D software products; SecurView Workstations; computer aided detection systems; and stereotactic breast biopsy systems. Further, it provides SculpSure, PicoSure, and MonaLisa Touch aesthetic treatment systems; TempSure, a radio frequency energy sourced platform; and MedLite and other products, and system components for medical aesthetics. Additionally, the company offers NovaSure, an endometrial ablation system to treat women suffering from abnormal uterine bleeding; MyoSure surgical products for removal of fibroids, and uterine polyps and other pathology; and Horizon DXA System and Fluoroscan Insight FD skeletal health products. It sells its products through direct sales and service forces, and a network of independent distributors and sales representatives. The company was founded in 1985 and is headquartered in Marlborough, Massachusetts.